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1. Introduction
The traditional antipsychotic drug development process is es-
sentially a trial-and-error approach (Carpenter and Koenig, 2008). 
New drugs were often developed as the result of duplicating 
the activity profile of the old antipsychotics, with slightly mod-
ified chemical structures (Valenstein, 1998). This drug discov-
ery process has produced a series of drugs acting at the D2 recep-
tor/5-HT2A receptors with similar efficacy as well as effectiveness 
against psychotic symptoms (Miyamoto et al., 2005), but has failed 
to produce novel antipsychotic drugs with novel molecular mech-
anisms. It appears that focusing solely on neuroreceptors as ther-
apeutic targets may not be a fruitful approach in the identification 
and development of better antipsychotic drugs. A bold shift going 
beyond traditional neuroreceptors is urgently needed.
In light of this, iptakalim is particularly interesting. It is a novel 
adenosine triphosphate (ATP)-sensitive potassium (KATP) chan-
nel opener that activates the cardiovascular KATP channels and 
exerts a strong antihypertensive effect (Wang et al., 2005a; Wang 
et al., 2005b). Because iptakalim was later found to be able to eas-
ily pass through the blood-brain-barrier and act on the neuronal 
plasma membrane and/or mitochondrial KATP channels, its poten-
tial therapeutic effects on neurological and neuropsychiatric dis-
orders have generated much interest (Hu et al., 2006; Wang et al., 
2006). Several lines of indirect evidence suggest that iptakalim may 
be potentially useful for schizophrenia and may offer needed ben-
efits for negative and cognitive symptoms. First, in vivo experi-
ments demonstrate that iptakalim has an inhibitory function on 
excess dopamine and glutamate release and can exert an intrinsic 
neuroprotective effect against necrosis, apoptosis and neurodegen-
erative disorders (Wang et al., 2004; Yang et al., 2006a; Yang et al., 
2006b; Zhang et al., 2007; Zhou et al., 2007). Second, in animal be-
havioral studies, iptakalim does not cause catalepsy (unpublished 
observation) and is shown to reverse haloperidol-induced cat-
alepsy and hypolocomotion (Wang et al., 2005c). Third, the target 
site of iptakalim—the KATP channel—is found in the neural circuits 
that are implicated in the pathophysiology of schizophrenia, such 
as the substantia nigra, ventral tegmental area, the prefrontal cor-
tex and hippocampus, and plays an important role in the regula-
tion of release of neurotransmitters, such as glutamate, dopamine 
and GABA (Ross et al., 2006). Finally, it has been hypothesized that 
the KATP channel activators may be beneficial for the treatment of 
schizophrenia (Allen and Etcheberrigaray, 1998; Freedman and Lin, 
1996) based on the evidence that dopamine receptors can modulate 
the KATP channel opening (Lin et al., 1993). Diazoxide, an ATP-sen-
sitive potassium channel opener, has been tried in the clinic as an 
adjunctive treatment together with haloperidol. It potentiated the 
effects of haloperidol on the positive and general psychopatholog-
ical symptoms of schizophrenia as measured by the Positive and 
Negative Syndrome Scale (PANSS) (Akhondzadeh et al., 2002).
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On the basis of the above evidence, we hypothesized that ip-
takalim is a novel drug with a therapeutic potential in schizophre-
nia. The primary aim of this study was to systematically validate 
its putative “antipsychotic” property using a variety of preclini-
cal animal models. Iptakalim was compared to haloperidol, clo-
zapine, and risperidone in tests predictive of antipsychotic activ-
ity. Specifically, we examined the effects of iptakalim treatment on 
(1) amphetamine—and phencyclidine —induced hyperlocomo-
tor activity; (2) rat conditioned avoidance responding; (3) amphet-
amine- and phencyclidine-induced prepulse inhibition (PPI) def-
icits and (4) c-Fos expression in the prefrontal cortex, the dorsal 
striatum, the nucleus accumbens and lateral septum nucleus.
2. Materials and methods
2.1. Animals
Adult male Sprague–Dawley rats (226–250 g upon arrival, Charles 
River, Portage, MI) were used. They were housed two per cage, 
in 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages 
under 12 h light/dark conditions (light on between 6:30 am and 
6:30 pm). Room temperature was maintained at 22 ± 1 °C with a 
relative humidity of 55–60%. Food and water was available ad li-
bitum. Animals were allowed at least one week of habituation to 
the animal facility before being used in experiments. All proce-
dures were approved by the Institutional Animal Care and Use 
Committee at the University of Nebraska-Lincoln.
2.2. Drugs
The injection solution of haloperidol (5.0 mg/ml ampoules, Si-
cor Pharmaceuticals, Inc, Irvine, CA) was obtained by mixing it 
with sterile water. The injection solutions of d-amphetamine sul-
fate (Sigma-RBI), phencyclidine hydrochloride (gift from NIDA 
Chemical Synthesis and Drug Supply Program), and fluoxetine 
(gift from the NIMH drug supply program) were obtained by 
mixing drugs with 0.9% NaCl solution. Clozapine and risperi-
done (gifts from the NIMH drug supply program) were dissolved 
in 1.0–1.5% glacial acetic acid in distilled water. Iptakalim hydro-
chloride (99.9%) was synthesized and provided by the Institute of 
Pharmacology and Toxicology, Academy of Military Medical Sci-
ences of China as a gift to Dr. Hu. Iptakalim was dissolved in ster-
ile water. Haloperidol, clozapine, risperidone, amphetamine and 
phencyclidine were administered subcutaneously, whereas fluox-
etine and iptakalim was administered intraperitoneally in a vol-
ume of 1.0 ml/kg of body weight.
2.3. Effects of iptakalim treatment on amphetamine-induced hy-
perlocomotion and phencyclidine-induced hyperlocomotion
Inhibition of locomotor hyperactivity induced by amphetamine 
or phencyclidine has been widely used as a screening tool for the 
“antipsychotic” property of a drug (Abekawa et al., 2007; Arnt, 
1995; Millan et al., 1999; Millan et al., 2008). In this experiment, 
we examined the effects of acute iptakalim treatment on amphet-
amine-induced and phencyclidine-induced hyperlocomotion and 
compared its effect with that of risperidone and fluoxetine (a se-
lective serotonin reuptake inhibitor with no known antipsychotic 
activity). After two days of habituation to the testing room and 
the testing boxes (30 min/day for 2 days), rats were first injected 
with the drug (i.e. risperidone 0.3 or 1.0 mg/kg, fluoxetine 5.0 or 
10.0 mg/kg, or iptakalim 10, 30 and 60 mg/kg) or vehicle on day 
3 and placed in the locomotor activity boxes for a period of 30 min 
for habituation. Each transparent polycarbonate box (48.3 cm L ×
 26.7 cm W × 20.3 cm H) was equipped with a row of 6 photocell 
beams (7.8 cm between two adjacent photobeams) to record the 
number of photocell beam breaks. At the end of the 30-min pe-
riod, rats were taken out and injected with amphetamine (1.5 mg/
kg, s.c.) or phencyclidine (3.2 mg/kg, s.c.) and placed back in the 
boxes for another 60 min. Locomotor activity (number of photo-
beam breaks) was measured throughout the entire 90 min testing 
session. The number of rats in each group was six to seven.
2.4. Effects of iptakalim treatment on rat conditioned avoidance 
responding
The conditioned avoidance response model is a well-established 
preclinical test for antipsychotic activity with high predictive va-
lidity (Arnt, 1982; Li et al., 2007; Wadenberg and Hicks, 1999). In 
this experiment, six custom-built two-compartment shuttle box 
systems (Med Associates, VT, USA) were used to train and test 
rats (see (Li et al., 2009a) and (Li et al., 2009b) for a detailed de-
scription of the apparatus). Sixty-six rats were first trained in a 
conditioned avoidance responding procedure for a total of eight 
sessions (~ 2 week period). Each training session consisted of 20 
trials. During each trial, if a subject moved from one compartment 
into the other within the 10 s of conditioned stimulus (76 dB white 
noise) presentation, the conditioned stimulus was terminated and 
the shock (unconditioned stimulus, US) was prevented, and this 
shuttling response was recorded as an avoidance. If the rat re-
mained in the same compartment for more than 10 s and made a 
crossing upon receiving the footshock, this response was recorded 
as an escape. If the rat did not respond during the entire 5 s pre-
sentation of the shock, the trial was terminated and escape failure 
was recorded. At the end of the training session, 39 rats reached 
training criterion (> 14 avoidance trials in each of the last two ses-
sions). They were then randomly assigned to one of six groups: ve-
hicle (water, n = 7), haloperidol (0.05 mg/kg, s.c., n = 5), clozapine 
(10 mg/kg, s.c., n = 6), iptakalim (10 mg/kg, i.p., n = 7), iptakalim 
(30 mg/kg, i.p., n = 7) and iptakalim (60 mg/kg, i.p., n = 7). On the 
drug test day (1 day later), each rat was tested at 30 and 90 min af-
ter drug administration, and each test session included 20 trials.
2.5. Effects of iptakalim treatment on amphetamine or phencycli-
dine-induced prepulse inhibition deficits
Reversal of amphetamine- and phencyclidine-induced PPI defi-
cits has been used as a tool to identify chemical compounds with 
antipsychotic activity (Geyer et al., 2001). In this experiment, we 
examined the effects of acute iptakalim treatment on amphet-
amine- and phencyclidine-induced PPI deficit and compared its 
effect with those of clozapine and haloperidol. Six startle moni-
tor systems (Kinder Scientific, Julian, CA) controlled by a PC were 
used. They were housed in compact sound attenuation cabinets 
(35.56 cm wide × 27.62 cm deep × 49.53 cm high). A speaker (di-
ameter: 11 cm) mounted on the cabinet’s ceiling was used to gen-
erate acoustic stimuli (70 dB–120 dB). The startle activity was mea-
sured by a piezoelectric sensing platform on the floor. After two 
days of handling and habituation to the PPI apparatus, sixty rats 
were given a subcutaneous injection of saline and subjected to a 
brief “matching” session. Ten minutes after receiving an injection 
of saline, rats were placed individually into the PPI boxes and ex-
posed to 5 min of 70 dB white background noise (which persisted 
through the entirety of the testing session) followed by 20 trials 
in pseudorandom order: 17 “PULSE ALONE” trials, each con-
sisting of a 40 millisecond (ms) 120 dB noise burst, and 3 “PRE-
PULSE + PULSE” trials consisting of a 20 ms 82 dB prepulse fol-
lowed 100 ms later by a 120 dB pulse. Startle magnitude was 
defined as the maximum force (measured in Newtons) applied by 
the rat to the startle apparatus recorded over a period of 100 ms 
beginning at the onset of the pulse stimulus. The average startle 
response to the PULSE ALONE trials was used to create balanced 
treatment groups such that all groups had comparable base-line 
startle magnitudes.
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The amphetamine testing began one day after the matching 
session. Rats were weighed and injected with either water, clo-
zapine (10.0 mg/kg), haloperidol (0.05 mg/kg), or one of three 
doses of iptakalim (10, 30 or 60 mg/kg) 20 min prior to the in-
jection of saline or amphetamine (3.0 mg/kg, s.c.), 10 min after 
which the rats were placed into the PPI boxes. Each testing ses-
sion lasted approximately 18 min and began with a 5 min period 
of 70 dB background noise followed by four different trial types: 
PULSE ALONE trials, and three types of PREPULSE + PULSE tri-
als, which consisted of a 20 ms 73, 76, or 82 dB prepulse (3, 6, and 
12 dB above background) followed 100 ms later by a 120 dB pulse 
(Culm and Hammer, 2004). Each session was divided into 4 blocks. 
Blocks 1 and 4 were identical, each consisting of 4 PULSE ALONE 
trials. Blocks 2 and 3 were also identical and each consisted of 8 
PULSE ALONE trials and 5 of each PREPULSE + PULSE trial 
type. A total of 54 trials were presented during each testing ses-
sion. Trials within each block were presented in a pseudorandom 
order and were separated by a variable intertrial interval aver-
aging 15 s (ranging from 9 to 21 s). Between each stimulus trial, 
100 ms of activity was recorded when no stimulus was present. 
These trials were called NOSTIM trials and were not included in 
the calculation of intertrial intervals. Responses recorded during 
NOSTIM trials are considered a measure of motor activity within 
the PPI boxes. Responses to the first 4 trials and last 4 trials, which 
consisted of 120 dB pulse stimuli, were not included in the final 
PPI analysis. The percent of PPI expressed within each test session 
was calculated using the standard PPI equation: (100 − (mean Pre-
pulse + Pulse response / mean Pulse response) / 100).
Following the amphetamine testing, rats were left alone for 
two days. One day later, they were re-assessed for PPI perfor-
mance under no drug treatment condition to ensure that there was 
no PPI difference among the groups prior to the phencyclidine 
testing, which was conducted one day later. The same PPI testing 
procedure was used with the only exception that the rats who had 
previously received amphetamine 3.0 mg/kg now received phen-
cyclidine 2.0 mg/kg. The rest of the treatment and testing proce-
dure remained unchanged. Phencyclidine at the chosen dose has 
been shown to induce a robust PPI deficit (Geyer et al., 2001).
2.6. Effects of iptakalim treatment on c-Fos expression in rats
The ability of antipsychotics to induce c-Fos protein in the fore-
brain regions has become a widely used molecular tool for identi-
fying drugs with potential antipsychotic activity and liability for ex-
trapyramidal side effects (EPS) (Mo et al., 2005; Natesan et al., 2006; 
Robertson and Fibiger, 1992; Robertson et al., 1994). This exper-
iment compared the acute effect of iptakalim on c-Fos expression 
in the four forebrain regions with that of haloperidol and clozap-
ine. Twenty-four rats were randomly assigned to 6 groups (n = 4/
group) and injected with either saline (vehicle), haloperidol 0.5 mg/
kg, clozapine 10.0 mg/kg, iptakalim 10 mg/kg, iptakalim 30 mg/
kg or iptakalim 60 mg/kg. Two hours after drug administration, 
the rats were anesthetized with sodium pentobarbital (100 mg/kg i.
p.), and their brains were removed after transcardial perfusion with 
saline followed by 4% paraformaldehyde. The brains were post-
fixed in 4% paraformaldehyde, transferred to 30% sucrose solutions 
until settled down, and then stored at − 80 °C until processing. The 
immunocytochemical procedure followed the protocol described 
in detail in our recent work (Zhao and Li, 2010). Fos immunoreac-
tive nuclei, labeled with antiserum raised in rabbits against the Fos 
peptide 4–17 amino acids of human Fos (Oncogene Research Prod-
ucts, Cambridge, MA, USA), were counted within a 870 × 650 µm2 
unit area unilaterally in three serial sections that were anatomically 
well-matched across the treatment groups. The brain regions ana-
lyzed included the medial prefrontal cortex, nucleus accumbens, 
dorsolateral striatum and lateral septal nucleus, corresponding to 
levels almost equal to Bregma 2.76 mm for medial prefrontal cor-
tex and nucleus accumbens, 1.80 mm for dorsal striatum and lateral 
septum nucleus according to Paxinos and Watson (2007). The val-
ues from four rats of each treatment group were averaged to obtain 
the final mean ± S.E.M.
In order to categorize iptakalim as a typical or atypical anti-
psychotic, we calculated the atypical index on the basis of the dif-
ference between the number of Fos-positive cells in the nucleus 
accumbens and dorsal striatum as described by Robertson et al. 
(1994). Briefly, the injection-corrected value in the nucleus accum-
bens and dorsal striatum was obtained by subtracting the number 
of Fos-positive nuclei in the vehicle-treated rats from that in the 
drug-treated ones. Atypical index was then yielded by subtracting 
the corrected number of Fos-positive cells in the dorsal striatum 
from that in the nucleus accumbens.
2.7. Statistical analysis
Data were expressed as mean values ± S.E.M and analyzed using 
one-way ANOVA followed by Post-hoc LSD tests to identify two-
group differences. If data contained a within-subject factor (e.g. 
test days, prepulse intensities), then a factorial repeated measures 
ANOVA was used. A conventional two-tailed level of significance 
at the 5% level was required.
3. Results
3.1. Effects of iptakalim treatment on amphetamine-induced hy-
perlocomotion and phencyclidine-induced hyperlocomotion
Figure 1A shows the mean motor activity of the eight groups dur-
ing the 60-min test period after amphetamine injection. Iptaka-
lim at 60 mg/kg and risperidone at both doses (0.3 and 1.0 mg/
kg) significantly inhibited the hyperlocomotion induced by am-
phetamine, whereas fluoxetine potentiated this effect. One-way 
ANOVA revealed that there was a significant main effect of treat-
ment (F(7,47) = 19.665, P < 0.001). Post-hoc tests showed that the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Effects of iptakalim, risperidone and fluoxetine pretreat-
ment on amphetamine- and phencyclidine-induced hyperlocomotion. 
The drugs or vehicle was administered 30 min prior to amphetamine 
or phencyclidine challenge. Rats were tested for 60 min following am-
phetamine (1.5 mg/kg, s.c.) injection (A) or phencyclidine (3.2 mg/
kg, s.c.) injection (B). *P < 0.05 in comparison to the vehicle + amphet-
amine or vehicle + phencyclidine group. 
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amphetamine-induced hyperlocomotion effect was significantly 
attenuated by iptakalim at 60.0 mg/kg (P = 0.038), risperidone at 
0.3 mg/kg (P = 0.001) and 1.0 mg/kg (P < 0.001), whereas it was 
significantly enhanced by fluoxetine at 10 mg/kg (P = 0.030) and 
marginally enhanced by iptakalim at 30 mg/kg (P = 0.072). None 
of the other treatments (iptakalim at other doses) affected the am-
phetamine-induced hyperlocomotion.
Figure 1B shows the mean motor activity of the seven groups 
of rats during the 60-min test period after vehicle or phencyclidine 
injection. Similar to their effects on amphetamine-induced hyper-
locomotion, risperidone at 0.30 mg/kg and iptakalim at 30 and 
60 mg/kg significantly inhibited phencyclidine-induced hyperlo-
comotion. One-way ANOVA revealed that there was a significant 
main effect of treatment (F(6, 47) = 10.072, P < 0.001). Post-hoc tests 
showed that in comparison to the vehicle treatment, phencyclidine 
produced a robust increase in motor activity (P < 0.001) which was 
significantly attenuated by iptakalim at 30 and 60 mg/kg and ris-
peridone at 0.3 mg/kg (P = 0.017, 0.012, and 0.006 respectively).
3.2. Effects of iptakalim treatment on rat conditioned avoidance 
responding
Figures 2A and B show the mean avoidances at three time points 
(predrug day and drug day 1 at 30 min and 90 min). At the 30 min 
point, iptakalim at 60 mg/kg significantly inhibited avoidance re-
sponding (P = 0.005), as did clozapine at 10 mg/kg (P < 0.001) 
and haloperidol at 0.05 mg/kg (P = 0.017). At the 90 min point, 
only clozapine still exerted a strong disruption of avoidance 
(P = 0.001).
3.3. Effects of iptakalim treatment on amphetamine or phencycli-
dine-induced prepulse inhibition deficits
Figure 3A shows the mean percent PPI of the seven groups of rats 
during the amphetamine test. Acute amphetamine (3.0 mg/kg, 
s.c.) treatment did not produce a robust disruption of PPI. Strik-
ingly, the combination of amphetamine and iptakalim produced 
a significant disruption on PPI. Repeated measures ANOVA re-
vealed a significant effect of group (F(6, 53) = 195.776, P < 0.001) 
and prepulse level (F(2, 106) = 99.155, P < 0.001), but no significant 
group × level interaction (F(12, 106) = 1.550, P = 0.118). In compar-
ison to the vehicle + vehicle condition, acute amphetamine slightly 
reduced %PPI, especially at the 3 dB (above background) level, 
but this effect was not statistically significantly (P = 0.101). In con-
trast, all three iptakalim groups (Ps < 0.001) and the haloperidol 
group (P = 0.019) showed significant lower %PPI than the vehi-
cle + vehicle group. The combined disruptive effect of iptakalim 
and amphetamine was also indicated by the finding that all three 
iptakalim groups differed significantly from the vehicle + amphet-
amine group (P = 0.010 for iptakalim 10 mg/kg and Ps < 0.001 for 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effects of iptakalim (10, 30 and 60 mg/kg, i.p.) (A), haloper-
idol (0.05 mg/kg, s.c.) and clozapine (10.0 mg/kg, s.c.) treatment (B) 
on conditioned avoidance response in rats tested at three time points 
(predrug day, 30 min and 90 min after drug administration). *P < 0.05 
in comparison to the vehicle group. 
Figure 3. Effects of iptakalim (10, 30 and 60 mg/kg, i.p.), haloperidol 
(0.05 mg/kg, s.c.) and clozapine (10.0 mg/kg, s.c.) treatment on am-
phetamine (3.0 mg/kg, s.c.)-induced PPI reduction (A) and startle re-
activity in prepulse and pulse trials (B) and NOSTIM trials (C). Hal-
operidol, clozapine, iptakalim or vehicle was injected 20 min prior to 
the injection of saline or amphetamine, 10 min after which, the rats 
were tested. *P < 0.05 in comparison to the vehicle + vehicle group; 
#P < 0.05 in comparison to the vehicle + amphetamine group. 
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the other two iptakalim groups). Clozapine pretreatment had little 
impact on PPI as there was no group difference between the clo-
zapine group and the vehicle + vehicle group (P = 0.481) nor the 
vehicle + amphetamine group (P = 0.351).
To examine the possible causes of the disruptive effect of com-
bined iptakalim + amphetamine on PPI, we examined the mean 
magnitude of acoustic startle responses (ASR) in the three prepulse 
(3, 6, 12 dB) and pulse alone (120 dB) trials. As can be seen in Fig-
ure 3B, iptakalim pretreatment preferentially enhanced the ASR 
magnitude in the prepulse trials over that in the pulse alone trials. 
One-way ANOVAs showed that the ASR magnitude in the three 
prepulse trials was significantly higher in the iptakalim groups 
than the vehicle + vehicle and vehicle + amphetamine groups (all 
Ps < 0.05 with the only exception of the iptakalim 10 mg/kg group 
at the 3 dB level, P = 0.115). For the ASR in the pulse alone trials, 
only the iptakalim 30 mg/kg group differed from the two vehicle 
groups (Ps < 0.013). Thus the lowered PPI in the iptakalim + am-
phetamine groups could be attributed to the preferentially in-
creased ASR magnitude in the prepulse trials over the pulse alone 
trials, an indication of PPI deficit (Swerdlow et al., 2001).
We also examined the startle magnitude in the NOSTIM tri-
als (no pulse) (Figure 3C). Responses recorded during NOSTIM 
trials are considered a measure of gross motor activity within 
the PPI boxes. Acute amphetamine enhanced the startle magni-
tude measured under this condition (P = 0.027 vs. vehicle). Ip-
takalim pretreatment with amphetamine further potentiated this 
effect. In comparison to the vehicle + vehicle group, all three ip-
takalim + amphetamine groups showed significantly higher star-
tle magnitude (Ps < 0.001), which was further enhanced by iptaka-
lim at 10 and 30 mg/kg (Ps < 0.005), and marginally enhanced by 
iptakalim at 60 mg/kg (P = 0.083).
On the pre-phencyclidine testing day (3 days after the am-
phetamine test), all groups showed comparable levels of PPI as 
no significant group difference was detected (F(6, 53) = 0.680, 
P = 0.667, data not shown). On the phencyclidine test day, all 
the phencyclidine-treated groups showed significantly lower 
%PPI at all three levels (see Figure 4A). There was a main ef-
fect of group (F(6,53) = 4.944, P < 0.001) and prepulse level 
(F(2,106) = 109.90, P < 0.001), but no significant group × level in-
teraction (F(12,106) = 0.983, P = 0.470). Post-hoc comparisons re-
vealed that acute phencyclidine 2.0 mg/kg significantly disrupted 
PPI (all Ps < 0.026). Pretreatment of haloperidol, clozapine and ip-
takalim did not reverse the phencyclidine-induced PPI deficits (all 
Ps > 0.05). In contrast, the iptakalim 30 mg/kg + phencyclidine 
group showed even lower %PPI than the vehicle + phencyclidine 
group (P = 0.039).
Figure 4B shows the mean magnitude of acoustic startle re-
sponses (ASR) in the three prepulse (3, 6, 12 dB) and pulse alone 
(120 dB) trials in the phencyclidine test. Acute phencyclidine 
treatment significantly increased the ASR magnitude at all 4 lev-
els (Post-hoc comparison, vehicle + vehicle vs. vehicle + phen-
cyclidine, P = 0.001), an effect that was completely reversed by 
pretreatment of clozapine (P = 0.003) and iptakalim at 60 mg/
kg (P = 0.043), and to a lesser extent by iptakalim at 10 mg/kg 
(P = 0.087). Pretreatment of haloperidol or iptakalim at 30 mg/kg 
had little effect on the ASR enhancing effect of phencyclidine (all 
Ps > 0.05 in comparison to the vehicle + phencyclidine group).
On the startle magnitude in the NOSTIM trials (no pulse), 
acute phencyclidine treatment significantly enhanced this mea-
sure (P = 0.001 between the vehicle + vehicle and vehicle + phen-
cyclidine groups, Figure 4C). This effect of phencyclidine was re-
versed only by clozapine pretreatment (P = 0.145 between the 
vehicle + vehicle and clozapine + phencyclidine group), but not 
by any other pretreatments.
3.4. Effects of iptakalim treatment on c-Fos expression in rats
Figure 5 shows the schematic representation of the forebrain re-
gions (rectangles) in which the c-Fos immunoreactive neurons 
were counted. As can be seen in Figure 6A and B, iptakalim at 30.0 
and 60.0 mg/kg, as well as haloperidol and clozapine produced 
significant increases in the number of Fos-positive neurons in the 
nucleus accumbens and lateral septum nucleus (all Ps < 0.05), 
whereas 10.0 mg/kg of iptakalim had no effect on c-Fos expres-
sion. In addition, haloperidol significantly increased Fos-positive 
neurons in the dorsal striatum (P < 0.001), whereas iptakalim and 
clozapine were without effect (P > 0.10). This similarity between 
iptakalim and clozapine was further confirmed by the atypical in-
dex (Robertson et al., 1994). As shown in Figure 6C, both iptakalim 
and clozapine, but not haloperidol, exhibited a positive atypical 
antipsychotic profile. Among the four brain areas that were exam-
ined, iptakalim produced effects similar to clozapine, but dissimi-
lar to haloperidol, and substantially increased c-Fos expression in 
the medial prefrontal cortex in comparison to other sites.
Figure 4. Effects of iptakalim (10, 30 and 60 mg/kg, i.p.), haloperidol 
(0.05 mg/kg, s.c.) and clozapine (10.0 mg/kg, s.c.) treatment on phen-
cyclidine (2.0 mg/kg, s.c.)-induced PPI deficit (A) and startle reac-
tivity in prepulse and pulse trials (B) and NOSTIM trials (C). Halo-
peridol, clozapine, iptakalim or vehicle was injected 20 min prior to 
the injection of saline or phencyclidine, 10 min after which, the rats 
were tested. *P < 0.05 in comparison to the vehicle + vehicle group; 
#P < 0.05 in comparison to the vehicle + phencyclidine group. 
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4. Discussion
This work was our first attempt to investigate the potential an-
tipsychotic activity of iptakalim. Using well-established animal 
models predictive of antipsychotic activity, we showed that ip-
takalim may possess a potential antipsychotic efficacy with some 
unique effects. Specifically, we found that iptakalim is effective in 
reducing both amphetamine- and phencyclidine-induced locomo-
tor activity, and suppressing avoidance responding, a behavioral 
profile shared with all currently used antipsychotics (Abekawa et 
al., 2007; Arnt, 1995; Millan et al., 1999; Millan et al., 2008; Sun et 
al., 2009; Wadenberg and Hicks, 1999). Neuroanatomically, iptaka-
lim also exhibits an antipsychotic profile. It dose-dependently in-
creased c-Fos expression in the nucleus accumbens, medial pre-
frontal cortex and lateral septal nucleus, but not in the dorsolateral 
striatum. All these findings are consistent with the behavioral and 
molecular profiles of antipsychotics. On the other hand, we also 
found that the combined iptakalim and amphetamine treatment 
produces a disruption of PPI. This finding seems inconsistent with 
the known antipsychotic profile. However, the combination of hal-
operidol and amphetamine also shows this effect, which suggests 
that this seemingly negative finding may not be sufficient to refute 
the potential antipsychotic activity of iptakalim.
In the present study, we found several similarities between ip-
takalim and clozapine. Both drugs showed an ability to attenuate 
phencyclidine-induced increase of startle reactivity in the PPI test 
(Figure 4B). They also disrupted avoidance responding and exhib-
ited a preferential action on c-Fos expression in the medial prefron-
tal cortex, nucleus accumbens and lateral septum nucleus over in 
the dorsal striatum. One notable difference between iptakalim and 
clozapine was their effects on the amphetamine-induced PPI re-
duction. Iptakalim in combination with amphetamine caused PPI 
deficits, whereas clozapine in combination with amphetamine did 
not. Haloperidol at the tested dose (0.05 mg/kg) in combination 
with amphetamine also caused PPI deficits. The potentiated ef-
fect of iptakalim and haloperidol was an unexpected finding, con-
trary to our expectation. It is puzzling given the fact that iptakalim 
showed an inhibitory effect on amphetamine-induced hyperloco-
motion and did not disrupt PPI when given alone (unpublished 
observation). In the literature, the effectiveness of antipsychotics 
in countering effects of indirect DA agonists such as amphetamine 
has not been examined thoroughly (Geyer et al., 2001). There are 
only a handful of reports showing that haloperidol blocks the ef-
fects of amphetamine on PPI (Andersen and Pouzet, 2001; Feifel et 
al., 1999). Thus, reversal of amphetamine-induced PPI deficit may 
not be a universal and well-established criterion for antipsychotic 
activity. Most PPI studies focus on the effect of antipsychotics on 
the direct DA agonist apomorphine because PPI is more sensitive 
to the effects of apomorphine than to the effects of amphetamine. 
Thus future work should examine how iptakalim treatment af-
fects apomorphine-induced disruption of PPI. Such work is cur-
rently being undertaken in our laboratory.
Similarly, we also did not observe any reversal effect of iptaka-
lim, clozapine or haloperidol pretreatment on phencyclidine-in-
duced PPI deficits. It has been commonly reported in the litera-
ture that typical antipsychotics such as haloperidol are ineffective 
in reducing the effects of phencyclidine and other NMDA antag-
onists on PPI in rats (see a comprehensive review (Geyer et al., 
2001)). Studies on atypical antipsychotics have not yielded consis-
tent results (Swerdlow et al., 1996). As noted by Geyer et al (2001), 
“clozapine, being the most tested atypical antipsychotic in the 
glutamatergic PPI model, has the largest number of inconsisten-
cies” probably due to its complex receptor mechanisms of action. 
Therefore, in the hindsight, the amphetamine and phencyclidine 
PPI models may not be the best choices to test antipsychotic activ-
ity of iptakalim, as they may have limited predictive value for an-
tipsychotic activity and pose a challenge for data interpretation. 
One possible reason is that they may reflect cognitive deficits of 
schizophrenia (as opposed to psychosis) (Swerdlow et al., 2008), 
which are less responsive to antipsychotic treatment.
Typical antipsychotics usually produce a large increase in c-
Fos expression in the dorsal striatum than in the nucleus accum-
bens, whereas atypical antipsychotics preferentially increase the 
c-Fos expression in the nucleus accumbens, having either little or 
no effect in the dorsal striatum. Our c-Fos immunocytochemistry 
study provided another line of evidence in support of the atyp-
ical antipsychotic property of iptakalim. This property is further 
supported by its exhibited atypical index (Robertson and Fibiger, 
1992; Robertson et al., 1994). One remarkable effect of iptaka-
lim was its strong action in the medial prefrontal cortex. In fact, 
among the four brain regions examined, iptakalim increased c-Fos 
expression more in the medial prefrontal cortex than in any other 
regions. The medial prefrontal cortex plays a critical role in var-
ious psychological functions, such as attention, memory, execu-
tive functioning and emotional regulations, all of which are found 
to be impaired to some extent in patients with schizophrenia (Be-
lujon and Grace, 2008; Moghaddam and Homayoun, 2008). Since 
clozapine’s actions on negative symptoms are thought to be asso-
ciated with its action in this region, the strong action of iptakalim 
in this region indicates that iptakalim may be particularly effica-
cious against negative symptoms and cognitive deficits in schizo-
phrenia by improving the function of the medial prefrontal cortex.
The putative target sites of iptakalim—the KATP channels—are 
the heteroctameric complexes, consisting of discrete pore-forming 
(inwardly rectifying potassium subunit; Kir6.1/Kir6.2) and regula-
tory subunits (sulfonylurea receptors; SUR1/SUR2). The channels 
are usually closed in normal conditions but are activated rapidly 
in response to a decrease in intracellular ATP/ADP ratio under 
metabolic stress or stoke or by selective channel openers. Open-
ing of KATP channels results in hyperpolarization of the cell mem-
brane and limitation of Ca2+ influx, thus blocking subsequent neu-
rotoxic biochemical cascades (Miki and Seino, 2005) and reducing 
neurotransmitter release. Because the KATP channels are widely 
distributed throughout the mammalian brain (Dunn-Meynell et 
al., 1998; Thomzig et al., 2005) and are found in the neural circuits 
that are implicated in the pathophysiology of schizophrenia, ip-
takalim might broadly impact brain functions by opening these 
Figure 5. Schematic representation of the forebrain regions (rectan-
gles) in which the c-Fos immunoreactive neurons were counted. Dis-
tance from bregma in the rostrocaudal planes is indicated. Drawings 
were modified from Paxinos and Watson (2007) with permission. 
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KATP channels and modulating glutamate and dopamine releases 
when the brain is under stress (in a sense, a dysfunctional schizo-
phrenic brain can be considered as under certain unknown stress) 
(Yang et al., 2008). We thus propose that amphetamine, phencycli-
dine or a conditioned stimulus (as in the avoidance task) increases 
dopamine and glutamate release in the nucleus accumbens and 
medial prefrontal cortex by activating dopaminergic neurons in 
the ventral tegmental area (VTA) (Abekawa et al., 2007; Bowyer et 
al., 1984; Hertel et al., 1995; Swanson and Schoepp, 2003; Zweifel 
et al., 2009). Iptakalim, by opening KATP channels located on the 
VTA dopamine neurons, inhibits dopamine and glutamate release 
(Wang et al., 2006; Yang et al., 2006b) and attenuates the behavioral 
and c-Fos expression effects induced by amphetamine, phencycli-
dine or conditioned stimulus.
The importance of potassium channels in schizophrenia as a 
valid target for future antipsychotic drugs is supported by a recent 
demonstration that retigabine, a selective KCNQ channel opener, 
exhibits an antipsychotic-like property in various preclinical an-
imal models (e.g., dopaminergic cell firing, amphetamine- and 
phencyclidine-induced hyperlocomotion and conditioned avoid-
ance response) (Sotty et al., 2008). KCNQ channels (also named 
Kv7) are voltage-dependent potassium channels that are found in 
the mesolimbic dopamine neurons. They share with KATP chan-
nels the property of inhibiting neuronal excitation. Another inter-
esting piece of evidence is that estrogen, which regulates the ac-
tivity of potassium large conductance calcium-activated channels 
known as BK channels (Dick and Sanders, 2001), has an antipsy-
chotic-like effect (Kulkarni et al., 2001).
We should point out several limitations with the present study. 
First, we used a limited number of behavioral models and c-Fos 
immunocytochemistry to identify the antipsychotic property of 
iptakalim. The exact molecular mechanisms responsible for ip-
takalim effects in these tests have not been addressed. Second, 
we have not compared iptakalim with other ATP-sensitive potas-
sium openers such as diazoxide in animal models of antipsychotic 
drugs, thus whether the KATP channels represent an effective 
Figure 6. (A) Representative images of effects of acute treatment with iptakalim (10, 30 and 60 mg/kg, i.p.), haloperidol (0.5 mg/kg, s.c.) and clo-
zapine (10.0 mg/kg, s.c.) on Fos expression in the four brain regions (e.g. medial prefrontal cortex, nucleus accumbens, dorsolateral striatum and 
lateral septal nucleus) in rats. Rats were sacrificed 2 h after vehicle or drug administration. (B) Quantification of effects of acute iptakalim, haloper-
idol or clozapine treatment on the mean number of Fos-positive neurons within a 870 × 650 µm2 area in the medial prefrontal cortex, nucleus ac-
cumbens, dorsolateral striatum and lateral septal nucleus (B). Each bar represents the mean + S.E.M of data from four rats. *P < 0.05 in comparison 
to the vehicle group. (C) Atypical index based on number of Fos-positive neurons in the dorsolateral striatum and nucleus accumbens. 
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novel target for future antipsychotics remain to be determined. 
Third, we did not examine to what extent iptakalim’s periph-
eral antihypertensive effect contributes to its behavioral effects as 
shown in this study, and we also have not examined the chronic 
effect of iptakalim treatment on other animal models of antipsy-
chotic drugs. Nevertheless, the present study provides important 
preliminary evidence suggesting that iptakalim may function as 
a novel antipsychotic drug. If iptakalim’s therapeutic potentials 
are confirmed, it would contribute to broader understanding of 
the neuropathophysiology of schizophrenia and intensify the ef-
fort to further examine the role of the KATP channel in the etiology 
of schizophrenia.
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